Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
 
Feedback
Home
c19early.org COVID-19 treatment researchSotrovimabSotrovimab (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

Summary of COVID-19 sotrovimab studies

Studies   Meta Analysis   Hide extended summaries

1,057 patient sotrovimab early treatment RCT: 89% lower ventilation (p=0.12), 75% lower progression (p=0.0004), and 79% lower combined mortality/hospitalization (p=0.0004).
RCT 1,057 outpatients, 529 treated with sotrovimab, showing significantly lower hospitalization >24h or mortality with treatment.

Dec 2021, JAMA, https://jamanetwork.com/journals/jama/fullarticle/2790246, https://c19p.org/gupta4

689 patient sotrovimab early treatment study: 81% lower mortality (p=0.0005) and 92% lower need for oxygen therapy (p<0.0001).
Retrospective 689 COVID-19 patients in Italy, showing lower mortality with sotrovimab treatment.

Aug 2023, Viruses, https://www.mdpi.com/1999-4915/15/8/1757, https://c19p.org/devito

10,036 patient sotrovimab early treatment PSM study: 89% lower mortality (p=0.05), 62% lower hospitalization (p=0.002), and 11% higher progression (p=0.55).
PSM retrospective 10,036 outpatients, 522 treated with sotrovimab, showing lower mortality and hospitalization with treatment.

Apr 2022, The J. Infectious Diseases, https://academic.oup.com/jid/article/226/12/2129/6586521, https://c19p.org/aggarwal

178 patient sotrovimab early treatment study: 35% lower hospitalization (p=0.46), 66% fewer combined hospitalization/ER visits (p=0.01), and 90% lower progression (p=0.009).
Retrospective high-risk outpatients in the USA, 82 treated with remdesivir, 88 with sotrovimab, and 90 control patients, showing significantly lower combined hospitalization/ER visits with both treatments in unadjusted results. The dominant variant was omicron B.1.1.529.

Jul 2022, J. Antimicrobial Chemotherapy, https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkac256/6652940, https://c19p.org/piccicacco

1,180 patient sotrovimab early treatment study: 74% lower combined mortality/ICU admission (p=0.001).
Analysis of 1,180 high-risk COVID-19 outpatients infected with Omicron BA.2 showing lower risk of death or ICU admission with sotrovimab treatment.

Dec 2023, J. Infection and Public Health, https://www.sciencedirect.com/science/article/pii/S1876034123004355, https://c19p.org/behzad

35,485 patient sotrovimab early treatment PSM study: 50% lower mortality (p=0.2), 12% lower combined mortality/hospitalization (p=0.7), 74% lower ICU admission (p=0.006), and 59% lower need for oxygen therapy (p<0.0001).
Retrospective 35,485 high-risk COVID-19 outpatients showing lower ICU admission and respiratory support with sotrovimab. There was no significant difference for hospitalization.

Jul 2024, PLOS ONE, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0304822, https://c19p.org/bell4

546,317 patient sotrovimab early treatment study: 24% lower combined mortality/hospitalization (p=0.0001) and 21% lower hospitalization (p=0.001).
N3C retrospective 4,992 high-risk outpatients with mild-to-moderate COVID-19 showing reduced risk of hospitalization or death with sotrovimab treatment compared to 541,325 untreated controls during periods of Delta and Omicron BA.2 variant predominance in the US (September 2021-April 2022).

Feb 2024, Clinical Drug Investigation, https://link.springer.com/10.1007/s40261-024-01344-4, https://c19p.org/bell3

94 patient sotrovimab early treatment study: 56% lower ICU admission (p=0.35) and 59% lower progression (p=0.05).
Retrospective 19 sotrovimab patients and 75 controls is Singapore, showing lower progression with treatment.

Mar 2022, Antibiotics, https://www.mdpi.com/2079-6382/11/3/345, https://c19p.org/ong2

1,688 patient sotrovimab early treatment study: 55% lower need for oxygen therapy (p<0.0001).
Retrospective 844 patients treated with sotrovimab and matched controls in Japan, showing lower risk of oxygen therapy with treatment.

May 2023, Viruses, https://www.mdpi.com/1999-4915/15/6/1300, https://c19p.org/miyashita2

5,790 patient sotrovimab early treatment study: 29% lower mortality (p=0.65), 50% lower combined mortality/hospitalization (p=0.07), and 57% lower hospitalization (p=0.05).
Retrospective 599 high-risk sotrovimab patients and 5,191 untreated controls, showing lower hospitalization/mortality with treatment, without statistical significance in the overall cohort. Efficacy was better for those ≥65, and efficacy was lower in later time periods.

Jul 2023, BMJ Open Respiratory Research, https://bmjopenrespres.bmj.com/lookup/doi/10.1136/bmjresp-2023-002238, https://c19p.org/drysdale

505 patient sotrovimab early treatment study: 75% lower mortality (p=0.55) and 60% lower hospitalization (p=0.35).
Retrospective 604 outpatients in the UK, showing lower risk of hospitalization with sotrovimab treatment, without statistical significance due to the small number of hospitalizations.

Mar 2023, PLOS ONE, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0281915, https://c19p.org/goodwin

6,052 patient sotrovimab early treatment study: 27% lower combined mortality/hospitalization (p=0.03).
Retrospective high risk outpatients in the UK, showing lower hospitalization/death with sotrovimab treatment. Residual confounding is likely with adjustments having no detail on specific comorbidities.

Jan 2023, J. Infection, https://www.sciencedirect.com/science/article/pii/S0163445323000828, https://c19p.org/evans2v

6,020 patient sotrovimab early treatment study: 50% lower combined mortality/hospitalization (p=0.005).
Retrospective 3,331 sotrovimab and 2,689 molnupiravir patients in the UK, showing lower risk of combined hospitalization/death with sotrovimab.

Nov 2022, BMJ, https://www.bmj.com/lookup/doi/10.1136/bmj-2022-071932, https://c19p.org/zheng4v

71,976 patient sotrovimab early treatment study: 16% lower combined mortality/hospitalization (p=0.002).
OpenSAFELY retrospective 75,048 outpatients in the UK, using the clone-censor-weight approach to address immortal time bias, showing lower combined mortality/hospitalization with sotrovimab treatment.

May 2023, medRxiv, https://www.medrxiv.org/content/10.1101/2023.05.12.23289914, https://c19p.org/tazarev

30,247 patient sotrovimab early treatment study: 38% lower mortality (p=0.62), 18% lower hospitalization (p=0.32), and 3% higher progression (p=0.83).
Retrospective 30,247 outpatients in the USA, showing no significant differences with sotrovimab with omicron BA.1.

Jun 2022, Int. J. Infectious Diseases, https://www.sciencedirect.com/science/article/pii/S1201971222005409, https://c19p.org/aggarwal2

2,571 patient sotrovimab early treatment study: 30% lower combined mortality/hospitalization (p=0.14).
Retrospective 2,571 patients treated with mAbs in the USA, and 5,135 control patients, showing lower combined mortality/hospitalization for bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, sotrovimab, and bebtelovimab, with statistical significance only for casirivimab/imdevimab.

Apr 2023, Annals of Internal Medicine, https://www.acpjournals.org/doi/10.7326/M22-1286, https://c19p.org/kipv

7,683 patient sotrovimab early treatment study: 4% lower combined mortality/hospitalization (p=0.91).
OpenSAFELY retrospective 7,683 outpatients in the UK, showing no significant difference in hospitalization/death between paxlovid and sotrovimab.

Jan 2023, medRxiv, https://www.medrxiv.org/content/10.1101/2023.01.20.23284849, https://c19p.org/zheng5v

1,929 patient sotrovimab early treatment study: 8% higher progression (p=0.73).
Retrospective 1,921 patients in Japan, showing no significant difference in progression with sotrovimab use.

Oct 2022, Research Square, https://www.researchsquare.com/article/rs-2118653/v1, https://c19p.org/suzuki2v

22,289 patient sotrovimab early treatment PSM study: 20% higher combined mortality/hospitalization (p=0.2).
Retrospective propensity-matched study of 22,289 high-risk COVID-19 outpatients in Canada, showing no significant difference in combined hospitalization/mortality with sotrovimab treatment. In a subgroup analysis of patients with no comorbidities, sotrovimab was associated with lower odds of severe outcomes. The study period included Omicron BA.1 and BA.2 variants, which may have contributed to the reduced efficacy compared to earlier studies.

Jun 2024, Int. J. Infectious Diseases, https://www.sciencedirect.com/science/article/pii/S1201971224002078, https://c19p.org/farmer

218 patient sotrovimab early treatment study: 20% higher severe cases (p=0.79).
Retrospective 218 COVID+ lung transplant patients in Germany, showing no significant difference in severe cases with early sotrovimab use.

Sep 2022, Infection, https://link.springer.com/10.1007/s15010-022-01914-8, https://c19p.org/kneidingerv

408 patient sotrovimab early treatment study: 258% higher hospitalization (p=0.15).
Retrospective 186 patients in the UK treated with sotrovimab, and 222 eligible but declining treatment, showing no significant difference in hospitalization. No group details are provided and the results are subject to confounding by indication.

Oct 2022, Open Forum Infectious Diseases, https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofac527/6750023, https://c19p.org/brown2v

360 patient sotrovimab late treatment RCT: 2% higher mortality (p=0.96) and 11% improved recovery (p=0.29).
RCT with 182 sotrovimab patients, 176 BRII-196+BRII-198 patients, and 178 control patients, median 8 days from symptom onset, showing no significant differences and terminated early due to futility.

Dec 2021, The Lancet Infectious Diseases, https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00751-9/fulltext, https://c19p.org/self3

420 patient sotrovimab late treatment PSM study: 140% higher mortality (p=0.12).
PSM retrospective 1,254 hospitalized patients in Germany, 147 treated with sotrovimab, showing higher mortality with sotrovimab, without statistical significance.

Dec 2022, Microbiology Spectrum, https://journals.asm.org/doi/10.1128/spectrum.04103-22, https://c19p.org/woo

928 patient sotrovimab early treatment study: 165% higher progression (p=0.19).
Retrospective 345 sotrovimab treated patients in Qatar matched with 583 patients that opted not to receive treatment, showing higher progression with treatment, without statistical significance.

Apr 2022, Int. J. Infectious Diseases, https://www.sciencedirect.com/science/article/pii/S1201971222005227, https://c19p.org/zaqout
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit